Literature DB >> 17297382

Safety trial of the vaginal microbicide cellulose sulfate gel in HIV-positive men.

Vicky Jespers1, Anne Buvé, Lut Van Damme.   

Abstract

OBJECTIVE: Cellulose sulfate (CS) is a promising vaginal microbicide. Because men will be exposed to the microbicide when engaging in vaginal intercourse, safety and acceptability need to be assessed in men.
DESIGN: This randomized double-blind phase I study assessed the safety and acceptability of seven consecutive daily doses of CS versus KY Jelly in 36 HIV-positive men.
RESULTS: No new or worsening of existing genital findings were observed during the follow-up examination. Mild genital symptoms were reported in 42% of CS users (itching, burning, tingling, testicular pain, dysuria, and warm or cold feeling) and 8% of KY Jelly users.
CONCLUSION: CS gel applied to the penis was well tolerated in this HIV-positive male population. The itching and burning symptoms were not severe and can be explained by the preservative benzyl alcohol present in the CS gel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17297382     DOI: 10.1097/01.olq.0000253340.76118.89

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  4 in total

Review 1.  Vaginal microbicides and the prevention of HIV transmission.

Authors:  Blayne Cutler; Jessica Justman
Journal:  Lancet Infect Dis       Date:  2008-11       Impact factor: 25.071

2.  Microbicide excipients can greatly increase susceptibility to genital herpes transmission in the mouse.

Authors:  Thomas R Moench; Russell J Mumper; Timothy E Hoen; Mianmian Sun; Richard A Cone
Journal:  BMC Infect Dis       Date:  2010-11-18       Impact factor: 3.090

Review 3.  Topical microbicides and HIV prevention in the female genital tract.

Authors:  Mackenzie L Cottrell; Angela D M Kashuba
Journal:  J Clin Pharmacol       Date:  2014-03-28       Impact factor: 3.126

4.  Application and removal of polyanionic microbicide compounds enhances subsequent infection by HIV-1.

Authors:  Vanessa Pirrone; Shendra Passic; Brian Wigdahl; Fred C Krebs
Journal:  Virol J       Date:  2012-01-26       Impact factor: 4.099

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.